X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will be primarily allocated to support TiumBio's clinical programs that include a Phase 2 trial of TU2670 (merigolix), a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in endometriosis.
Lead Product(s): Merigolix
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: TU2670
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Tiumbio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Private Placement December 29, 2023
Details:
SKYCovion contains nanoparticles of recombinant Receptor Binding Domain (RBD) of SARS-CoV-2 Spike (S) protein from the parental D614G strain and an adjuvant system (AS03) and got approval by MHRA for treating COVID-19 infection.
Lead Product(s): Recombinant Adjuvanted Covid-19 Vaccine,AS03
Therapeutic Area: Infections and Infectious Diseases Product Name: SKYCovion
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2023
Details:
Skycovion,a vaccine for protecting against Covid-19 has small particles known as nanoparticles containing parts of the spike protein found on the surface of SARS-CoV-2.
Lead Product(s): SARS-CoV-2 Surface Spike Protein,Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Skycovion
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 20, 2022
Details:
The compound in the patent was discovered by Standigm Insight™. In a mouse model, it showed comparable or better improvements in its rheumatoid arthritis disease activity score than reference drugs such as methotrexate and hydroxychloroquine.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: Standigm
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
AriBio completed enrollment in a Phase 2 study of AR1001, a first in class, orally dosed investigational drug for mild to moderate Alzheimer’s disease.
Lead Product(s): Methylbenzylamine
Therapeutic Area: Neurology Product Name: AR1001
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: AriBio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
